Coronary thrombosis in chronic myocardial ischemia;Die Bedeutung der Koronarthrombose fur die chronische Myokardischamie

Zeitschrift fur Kardiologie

Volumn 86, Issue SUPPL. 1, 1997, Pages 71-83

  Schoehel, F C ^a   Gradaus, F ^a   Jax, T W ^a   Stiegler, H M ^a   Stein, D A ^a   Borries, M ^a   Kelm, M ^a   Strauer, B E ^a   Leschke, M ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

antithrombotic therapy; coronary artery disease; progression; PTCA; restenosis; thrombus

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; COUMARIN DERIVATIVE; DIPYRIDAMOLE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TICLOPIDINE; UROKINASE; FIBRINOLYTIC AGENT;

CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; HUMAN; REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY; ANGINA PECTORIS; CORONARY BLOOD VESSEL; HEART MUSCLE ISCHEMIA; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; RECURRENT DISEASE;

ANGINA PECTORIS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; COMBINED MODALITY THERAPY; CORONARY THROMBOSIS; CORONARY VESSELS; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL ISCHEMIA; PROGNOSIS; RECURRENCE;

EID: 0030906479     PISSN: 03005860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (115)

1. Alderman EL, Corley SD, Fisher LD, Chaitman BR, Faxen DP, Foster ED, Killip T, Sosa JA, Bourassa MG, CASS Participating Investigators and Staff (1993) Five-year angiographic follow-up of factors associated with progression of coronary artery disease in the Coronary Artery Surgery Study (CASS). J Am Coll Cardiol 22: 1141-1154
2. Badimon L, Badimon JJ, Turitto VT, Vallabahjosula S, Fuster V (1988) Platelet thrombus formation on collagen Type I - Influence of blood rheology, von Willebrand factor and blood coagulation. Circulation 78: 1431-1442
3. Bar-Shavit R, Benezra M, Eldor A, Hy-Am E, Fenton JW, Wilner GD (1990) Thrombin immobilized to extracellular matrix is a potent mitogen for vascular SMC: Nonenzymatic model of action. Cell Regulation 1: 453-463
4. Barstad RM, Orvim U, Hamers MJAG, Tjonnfjord GE, Brosstad FR, Sakariassen KS (1996) Reduced effect of aspirin on thrombus formation at high shear and disturbed laminar flow. Thromb Haemostas75: 827-832
5. Bauters C, Lablanche JM, McFadden EP, Hamon N, Bertrand ME (1995) Relation of coronary angioscopic findings at coronary angioplasty to angiographic restenosis. Circulation 92: 2473-2479
6. Bini A, Fenoglia JJ, Mesa Tejeda R, Kudryk B, Kaplan KL (1989) Identification and distribution of fibrinogen, fibrin and fibrino(gen) degration products in atherosclerosis: use of monoclonal antibody. Atherosclerosis 9: 109-121
7. Broadhurst P, Kelleher C, Hughes L (1990) Fibrinogen, factor VII clotting activity and coronary artery disease severity. Atherosclerosis 85: 169-173
8. Brown BG, Bolson EL, Pierce CD, Petersen RB, Wong M, Dodge HT (1983) Progression of native coronary atherosclerosis is not altered by aspirin plus dipyridamole. Circulation 68 (Suppl. III): 398
9. Buchanan MR, Rischke JA, Hirsh J (1982) Aspirin inhibits platelet function independent of the acetylation of cyclooxygenase. Thromb Res 25: 363-373
10. Ceriello A, Pirisi M, Giacomello R, Stel G, Falleti E, Motz E, Lizzio S, Gonano F (1994) Fibrinogen plasma levels as a marker of thrombin activation: New insights on the role of fibrinogen as a cardiovascular risk factor. Thromb Haemostas 71: 593-595
11. Chesebro JH, Webster MWI, Smith HC, Frye RL, Holmes DR, Reeder GS, Bresnahan DR, Nishimura A, Clements IP, Bardsley WT, Grill DE, Fuster V (1989) Antiplatelet therapy in coronary disease progression: Reduced infarction and new lesion formation. Circulation 80 (Suppl. II): 266
12. Dahl J vom, Uehis R, Fechtrup C, Kerber S, Thompson S, Marzilli M, Bertina R, Haverkate F für die ECAT Studiengruppe (1996) Hämostaseologische Parameter sind nicht zur Vorhersage der Akutergehnisse und des Rezidivrisikos bei elektivev Kovonavangioplastie (PTCA) in Patienten mit stabiler Angina pectoris geeignet. Z Kardiol 85 (Suppl. 2) 222
13. Darius H, Sellig S, Belz GG, Darius BN (1994) Aspirin 500 mg/d is superior to 100 and 40 mg/d for prevention of restenosis following PTCA. Circulation 90: I-651
14. Davies MJ, Bland JM, Hangartner JRW, Angelini A, Thomas AC (1989) Factors influencing the presence or absence of acute coronary syndromes in sudden ischemic death. Eur Heart J 10: 203-208
15. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J (1993) Risk of thrombosis in human atherosclerotic plaques: Role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 69: 377-381
16. Douglas JS, Lutz JF, Clements SD, Robinson PH, Roubin GS, Lembo NJ, King SB (1988) Therapy of large intracoronary thrombi in candidates for percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 11: 238A
17. Ellis SG, Roubin GS, King SB, Douglas JS, Weintraub WS, Thomas RG, Cox WR (1988) Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty. Circulation 77: 372-379
18. Ellis SG, Roubin GS, Wilentz J, Douglas JS, King SB (1989) Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. Am Heart J 117: 777-782
19. Ernst E, Resch L (1994) Fibirinogen as a cardiovascular risk factor: A metaanalysis and review of the literature. Ann Intern Med 118: 956-963
20. Falk E (1989) Morphologic features of unstable atherothrombotic plaques underlying acute coronary syndromes. Am J Cardiol 63 (Suppl. E): 114E-120E
21. Falk E, Shah PK, Fuster V (1995) Coronary plaque disruption. Circulation 92: 657-671
22. Faxon DP, Spiro TE, Minor S, Cote G, Douglas J, Gottlieb R, Califf R, Dorosti K, Topol E, Gordon JB, Ohmen M and the ERA Investigators (1994) Low molecular weight heparin in prevention of restenosis after angioplasty - Results of Enoxaparin Restenosis (ERA) Trial. Circulation 90: 908-914
23. Fernandez-Orliz A, Badimon JJ, Falk E, Fuster V, Mexer B, Mailhac A, Weng D, Shah PK, Badimon L (1994) Characterization of the relative thrombogenicity of atherosclerotic plaque components: Implications for consequences of plaque rupture. J Am Coll Cardiol 23: 1562-1569
24. Fishman RF, Kuntz RE, Carrozza JP, Miller MJ, Senerchia CC, Schnitt SJ, Diver DJ, Safian RD, Baim DS (1992) Long-term results of directional atherectomy: Predictors of restenosis. J Am Coll Cardiol 20: 1101-1110
25. Fuster V, Badimon L, Badimon J, Chesebro J ( 1992) The pathogenesis of coronary artery disease and the acute coronary syndromes (First of two parts). N Engl J Med 326: 242-250
26. Fuster V, Badimon L, Badimon J, Chesebro J (1992) The pathogenesis of coronary artery disease and the acute coronary syndromes (Second of two parts). N Engl J Med 326: 310-318
27. Fuster V, Falk E, Fallon JT, Badimon L, Chesebro JH, Badimon JJ (1995) The three processes leading to post PTCA restenosis: dependence on the lesion substrate. Thromb Haemostas 74 (Suppl. 1): 552-559
28. Gaspari F, Vigano G, Orisio S, Bonati M, Livio M, Remuzzi G (1987) Aspirin prolongs bleeding time in uremia by mechansims distinct from platelet cyclooxygenase inhibition. J Clin Invest 79: 1788-1797
29. Giroud D, Li JM, Urban P, Meier B, Rutishauser W (1992) Relation of the silo of myocardial infarction to the most severe coronary stenosis at prior angiograpliy. Am J Cardiol 69: 729-732
30. Gotto A (1995) Lipid lowering, regression and coronary events. A review of the Interdisciplinary Council on Lipids and Cardiovascular Risk Intervention. Seventh council meeting. Circulation 92: 646-656
31. Gurewich V, Lipinski B, Hyde E (1976) The effect if the fibrinogen concentration and the leukocyte count on intravascular fibrin deposition from soluble fibrin monomer complexes. Thromb Haemostas 36: 605-614
32. Harrison (1991) Endothelial modulation of vascular tone: Relevance to coronary angioplasty and restenosis. J Am Coll Cardiol 17: 71B-76B
33. Heijer P den, Dije RB van, Hillege HL, Pentinga ML, Serruys PW, Lie KI (1994) Serial angioscopic and angiographic observations during the first hour alter successful coronary angioplasty: A preamble to a multicenter trial addressing angioscopic markers of restenosis. Am Heart J 128: 656-663
34. Heintzen MP, Strauer BE (1994) Interventionelle Strategien bei kritischen Situationen der koronaren Herzkrankheil. Imensivmed 31: 277-287
35. Holmes DJ, Vliestra RE, Smith HC, Vetrovec GW, Kent KM, Cowley MJ, Faxon DP, Grüntzig AR, Kelsey SF, Detre KM, Raden MJ, Mock MB (1984) Restenosis after percutaneous transluminal coronary angioplasty (PTCA): A report from the PTCA Registry of the National Heart, Lung and Blood Institute. Am J Cardiol 53: 77c-81c
36. Huber K, Jörg M, Probst P, Schuster E, Lang I, Kaindel F, Binder BR. A decrease in plasminogen activator inhibitor-1 activity after successful percutaneous transluminal coronary angioplasty is associated with a significantly reduced risk for coronary restenosis. Thromb Haemostas 1992; 67: 209-213
37. Ikeda Y, Handa M, Kawano K, Kamata T, Murata M, Araki Y, Anbo H, Kawai Y, Watanabe K, Itagaki I, Sakai K, Ruggeri ZM. The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. J Clin Invest 87: 1234-1240
38. Ip JH, Fuster V, Badimon L, Badimon JJ, Taubman MB, Chesebro JH (1990) Syndromes of accelerated atherosclerosis: Role of vascular injury and smooth muscle cell proliferation. J Am Coll Cardiol 15: 1667-1687
39. Itoh A, Miyazaki S, Nonogi H, Daikoku S, Haze K (1995) Angioscopic prediction of successful dilatation and restenosis in percutaneous transluminal angioplasty significance of yellow plaque. Circulation 91: 1389-1396
40. Kirschstein W, Simianer S, Dempfle CE, Keller H, Stegaru B, Rentrop P, Heene DL (1989) Impaired fibrinolytic capacity and tissue plasminogen activator release in patients with restenosis after percutaneous transluminal coronary angioplasty (PTCA). Thromb Haemostas 62: 772-775
41. Koenig W, Ernst E (1992) The possible role of hemorheology in atherothrombogenesis. Atherosclerosis 94: 93-107
42. Konstantopoulos K, Kamat SG, Schafer AI, Banez EI, Jordan R, Kleiman NS, Heliums JD (1995) Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment c7E3 Fab, in patients undergoing coronary angioplasty. Circulation 91: 1427-1431
43. Kranzhöfer R, Clinton SK, Fenton JW. Libby P (1994) Thrombin potently induces cytokine production by vascular smooth muscle cells but not by monocytes/macrophages. Ciculation 90: I-636
44. Kunert M, Sorgenicht R, Scheuble L, Ketteler T, Lürken E, Meyer I, Muller A, Emmerich K, Gülker H (1996) Der Stellenwert der aktivierten Gerinnungszeit (ACT) in der Überwachung der Antikoagulalionbei Koronarangioplastie. Z Kardiol 85: 118-124
45. Kurz T, Rauch B, Kübler W (1991) Antianginöse Therapie der koronaren Herzerkrankung. Monooder Kombinationsbehandlung. Z Kardiol 180: 305-316
46. Lefkovits J, Plow PF, Topol EJ (1995) Platelet glycoprotein IIb/IIIa receptors in cardiovascular disease. N Engl J Med 332: 1533-1559
47. Leimgruber PP, Roubin GS, Hollman J, Cotsonis GA, Meier B, Douglas JS, King SB, Gruentzig AR (1986) Restenosis after successful coronary angioplasty in patients with single vessel disease. Circulation 73: 710-717
48. Leschke E (1929) Entstehung und Verlauf der Angina pectoris und Coronarthrombose. Klin Wschr 8: 2289-2293
49. Leschke M, Blanke H, Stellwaag M, Motz W, Strauer BE (1988) Hyperfibrinogenämie und pathologische Plasmaviskosität. Dtsch Med Wschr 113: 1175-1181
50. Leschke M, Höffken H, Motz W, Blanke H, Schoebel FC, Strauer BE (1992) Chronisch-intermittierende Urokinasetherapie bei therapierefraktärcr Angina pectoris. Dtsch Med Wschr 117: 81-7
51. Leschke M, Schoebel FC, Mecklenbeck W, Stein D, Jax TW, Strauer BE (1996) Long-term intermittent urokinase therapy in end-stage coronary artery disease and refractory angina pectoris: A randomized dose-response trial. J Am Coll Cardiol 27: 575-584
52. Little WC, Constantinescu M, Appelgate RJ, Kutcher MA, Burrows MT, Kahle FR, Santamore WP (1988) Can coronary angiography predict the site of subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease. Circulation 78: 1157-1166
53. Mailhac A, Badimon JJ, Fallen JT, Fernandez-Ortiz A, Meyer B, Chesebro JH, Fuster V, Badimon L (1994) Effect of an eccentric severe stenosis on fibrin(ogen) deposition on severely damaged vessel wall in arterial thrombosis - Relative contribution of fibrin(ogen) and platelets. Circulation 90: 988-996
54. Maresta A, Balducelli M, Cntini L, Casari A, Chioin R, Fabbri M, Fontanelli A, Preti PAM, Repetto S, De Servi S, Varani for the STARC Investigators (1994) Trapidil (triazolpyrimidine), a platelet-derived growth facto antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty - Results of the randomized, double-blind STARC Study. Circulation 90: 2710-2715
55. Marumara JD, Merlini PA, Sharma SK, Khagan N, Torre SR, Israel DH, Ardissino D, Ambrose JA (1994) Thrombin generation in human coronary arteries after percutaneous balloon angioplasty. J Am Coll Cardiol 24: 1484-1491
56. McNamara CA, Sarembrock I, Gimpel L, Fenton J, Coughlin SR, Owens GK (1993) Thrombin stimulates proliferation of cultured rat aortic SMC by a proteolitically activated receptor. J Clin Invest 91: 94-98
57. Melandri G, Semprini F, Cervi V, Candiotti N, Palazzini E, Branzi A, Magnami B (1993) Benefit of adding low molecular weight heparin to the conventional treatment of stable angina pectoris: a double-blind, randomized, placebo-controlled trial. Circulation 88: 2517-23
58. Merlini PA, Bauer KA, Oltrona L, Ardissino d, Cattaneo M, Belli C, Mannucci PM, Rosenberg RD (1994) Persistent activation of coagulation mcchansims in unstable angina and myocardial infarction. Circulation 90: 61-68
59. Mest KJ (1990) Trapidil: A potent inhibitor of platelet aggregation. J Drug Rev 3: 143-149
60. Meyer BJ, Badimon JJ, Mailhac A, Fernanadez-Otiz A, Chesebro JH, Fuster V, Badimon L (1994) Inhibition of growth of thrombus on fresh mural thrombus - Targeting optimal therapy. Circulation 90: 2432-2438
61. Meyer BJ, Fernandez-Ortiz A, Mailhac A, Falk E, Badimon L, Michael AD, Chesebro JH, Fuster V, Badimon JJ (1994) Local delivery of r-Hirudin by a double-ballon perfusion catheter prevents mural thrombosis and minimizes platelet deposition after angioplasty. Circulation 90: 2474-2480
62. Mickelson JK, Hoff PT, Homeister JW, Fantone JC, Lucchesi BR (1993) High dose intravenous aspirin, not low dose intravenous or oral aspirin, inhibits thrombus formation and stabilizes blood flow in experimental coronary vascular injury. J Am Coll Cardiol 21: 502-510
63. Mizuno K, Miyamoto A, Satomura K, Kurita T, Arai T, Masami S, Yanagida S, Nakamura H (1991) Angioscopic coronary morphology in acute coronary disorders. Lancet 337: 809-812
64. Montalescot G, Ankri A, Vicaut E, Drobinski G, Grosgogeat Y, Thomas D (1995) Fibrinogen after coronary angioplasty as a risk factor for restenosis. Circulation 92: 31-38
65. Moreno P, Falk E, Palacios I, Newell JB, Fuster V, Fallon JT (1994) Macrophage infiltration in acute coronary syndromes - Implications for plaque rupture. Circulation 90: 775-778
66. Mufson L, Black A, Roubin G, Wilentz J, Mead S, McFarland K, Weintraub W, Douglas JS, King SB (1988) A randomized trial of aspirin in PTCA: Effect of high vs. low dose aspirin on major complications and restenosis. J Am Coll Cardiol 11 (Suppl. 1): 236A
67. Nakagawa S, Hanada Y, Koiwaya Y, Tanaka K (1988) Angiographic features in prolonged anticoagulation: Role of ruptured atheromatous plaque and adherent thrombus in acute myocardial infarction in vivo. Circulation 78: 1335-1344
68. Narins CR, Hillegass WB, Nelson CL, Tcheng JE, Harrington RA, Phillips HR, Stack RS, Califf RM (1996) Relation of activated clotting time during angioplasty and abrupt closure. Circulation 93: 667-671
69. Nelken NA, Soiler J, O Keefe J, Vu TK, Charo I, Coughlin S (1992)Thrombin receptor expression in normal and atherosclerotic human arteries. J Clin Invest 90: 1614-1622
70. Nishikawa H, Ono N, Motoyasu M, Aoki T, Shimizu Y (1992) Preventive effects of trapidil on restenosis after PTCA. Circulation 86 (Suppl. I): I-53
71. Nobuyoshi M, Kimura T, Nosaka H, Mioka S, Ueno K, Yokoi H, Hamasaki N. Horiuchi H, Ohishi H (1988) Restenosis after successful percuataneous transluminal coronary angioplasty: Serial angiographic follow-up in 229 patients. J Am Coll Cardiol 12: 616-623
72. Nobuyoshi M, Tanaka M, Nosaka H, Kimura T, Yokoi H, Hamasaki N, Kim K, Shindo T, Kimura K (1991) Progression of coronary atherosclerosis: is coronary spasm related to progression? J Am Coll Cardiol 18: 904-910
73. Ohnishi H, Yamaguchi K, Shimada S, Suzuki Y, Kumagai A (1982) A new approach to treatment of atherosclerosis and tarpidil as an antagonist to platelet-derived growth factor. Life Sci 31: 2595-2602
74. Okamato S, Inden M, Setsuda M, Konishi T, Nakano T (1992) Effects of trapidil (triazolopyridine), a platelet derived growth factor antagonist, in preventing restenosis after percutaneous transluminal coronary angioplasty. Am Heart J 123: 1439-1444
75. Ouigley PJ, Hlatky MA, Hinohara, Rendall DS, Perez JA, Phillips HR, Califf RM, Stack RS (1989) Repeat percutaneous transluminal coronary angioplasty and predictors of recurrent restenosis. Am J Cardiol 63: 409-413
76. Quyyumi AA, Diodati JG, Lakatos EE, Bonow RO, Epstein SE (1993) Angiogenic effects of low molecular weight heparin in patients with stable coronary artery disease: A pilot study. J Am Coll Cardiol 22: 635-41
77. Ranke C, Hecker H, Creutzig A, Alexander K (1993) A dose-dependent effect of aspirin on carotid atherosclerosis. Circulation 87: 1873-1879
78. Richardson PD, Davies MJ, Born GVR (1989) Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 2: 941-944
79. Ross R (1992) The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 362: 801-809
80. Ruef J, Papadaki M, Eskini SG, McIntire LV, Runge MS (1996) Fluid shear stress regulates the expression of human thrombin receptor and plasminogen activators in vitro. Ann Hematol 173(Suppl. I) S 49
81. Sakata K, Miura F, Sugino H, Shinobe M, Shirotani M, Yoshida H, Mori N, Hoshino T, Takada A (1996) Impaired fibrinolysis early after percutaneous transluminal coronary angioplasty is asscociated with restenosis. Am Heart J 131: 1-6
82. Sarembock IJ, Gertz SD, Gimple LW, Owen RM. Powers ER, Roberts WC (1991) Effectivenes of recombinant desulphatohirudin in reducing restenosis after balloon angioplasly of atherosclerotic femoral arteries in rabbits. Circulation 84: 232-243
83. Schanzenbacher P, Grimmer M, Maisch B, Kochsick K (1988) Effect of high and low dose aspirin on restenosis after primary successful Angioplasty. Circulation 78 (Suppl. 2): 11-99
84. Schmid-Schonbein H (1988) Thrombose als Vorgang in "strömendem Blut": Wechselwirkungen fluiddynamischer, theologischer und enzymologischer Ereignisse beim Ablauf von Thrombozytenaggregation und Fibrinpolymerisation. Hämostaseologie 8: 149-173
85. Schnitt SJ, Safian RD, Kuntz RE, Schmidt DA, Baim DS (1992) Histologie findings obtained by percutaneous directional atherectomy. Hum Pathol 23: 415-420
86. Schneidau A, Harrison MJG, Hurst C, Wilkers HC, Meade TW (1989) Arterial disease risk factors and angiographic evidence of atheroma of the carotid artery. Stroke 20: 1466-1471
87. Schocbel FC, Leschke M, Jax TW, Stein D, Strauer BE (1996) Chronic-intermittent urokinase therapy in patients with end-stage coronary artery disease and refractory angina pectoris: A pilot study. Gin Cardiol 19: 115-120
88. Schoebel FC, Stein D, Borries M, Heintzen M, Leschke M, Sirauer BE (1996) Instabile Angina pectoris - Pathogenese, Risikostrutifizierung und Therapie. Disch Med Wschr 121: 310-317
89. Schoebel FC, Gradaus F, Jax TW, Stein D, Heins M, Borries M, Heintzen MP, Leschke M, Strauer BE (1996) Hämostascologische Risikofaktoren - Einfluß auf die Restenoserate nach elektiver PTCA. Z Kardiol 84 (Suppl. 1), 284
90. Schroer K (1995) Antiplatelet drugs - A comparative review. Drugs 50: 7-28
91. Schumacher M, Eber B, Tiran A, Toplak H, Luha O, Gasser R, Klein W (1992) Fibrinogen values in patients with and without restenosis following percutaneous transluminal coronary angioplasty. Cardiology 80: 345-348
92. Schwartz L, Bourassa MG, Lesperance J, Aldrige HE, Kazim F, Salvatori VA, Henderson M, Bonan R, David PR (1988) Aspirin and Dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 318: 1714-1719
93. Seifert RA, Schwartz SM, Bowen-Pope DF (1984) Developementally regulation of platelet-derived growth factor-like molecules. Nature 311: 669-671
94. Serruys PW, Luijten HE, Beatt KJ, Geuskens R Feyter PJ de, Brand M van den, Reiber JHC, Katen HJ ten, Es GA van, Hugenholtz PG (1988) Incidence of restenosis after successful coronary angioplasty: A time related phenomenon. A quantitative angiographie study in 342 consecutive patients at 1, 2, 3 and 4 months. Circulation 77: 361-371
95. Serruys PW, Herman JPR, Simon R, Rutsch W, Bode Ch, Laarman GJ, Dijk R van, Close P, Deckers JW for the HELVETICA Investigators (1995) A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med 333: 757-763
96. Shah PK, Amin J (1992) Low high density lipoprotein level is asscoiatcd with increased restenosis rate after coronary angioplasty. Circulation 85: 1279-1285
97. Snub C (1990) Stable angina pectoris: 3. Medical treatment. Mayo Clin Proc 65: 256-273
98. Smith EB, Alexander KM, Massie IB (1976) Insoluble fibrin in human aortic intima. Quantiative studies on the relationship between insoluble fibrinogen and low-density lipoprotein. Atherosclerosis 23: 19-25
99. Smith EB, Keen GA, Grunt A, Stirk C (1990) Fate of fihrinogen in human arterial intima. Arteriosclerosis 10: 263-275
100. Stein D, Schoebel FC, Heins M, Withold W, Pels K, Jax T, Reinauer H, Leschke M, Strauer BE (1995) Activation of the fibrinolytic system in patients with hyperfibrinogenemia and coronary artery disease. Ann Haematol 70 (Suppl. 1): 359
101. Taylor RR, Gibbons FA, Cope GD, Cumpston GN, Mews GC, Luke P (1991) Effects of low-dose aspirin on restenosis after coronary angioplasty. Am J Cardiol 68: 874-878
102. Thieme T, Wernecke KD, Meyer R, Brandenstein E, Habedank D, Hinz A., Felix SB, Baumann G, Kleber FX (1996) Angioscopic evaluation of atherosclerotic plaques: Validation by histomorphological analysis and association with stable and unstable coronary syndromes. J Am Coll Cardiol 28: 1-6
103. Thornton MA, Grüntzig AR, Hollman J, King SB, Douglas JS (1984) Coumadin and aspirin in prevention of recurrence after transluminal coronary angioplasty: A randomized study. Circulation 69: 721-727
104. Tiell ML, Sussmann I, Gordon PB, Sanders RN (1983) Suppression of fibroplast proliferation in vitro and of neointimal hyperplasia in vivo by triazolopyrimidine, trapidil. Artery 12: 33-50
105. Tomaru T, Nakamura F, Fujimori Y, Omata M, Kawai S, Okada R, Murata Y, Uchida Y (1995) Local treatment with antithrombotic drugs can prevent thrombus formation: an angioscopic and angiographic study. J Am Coll Cardiol 26: 1325-1332
106. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M, Sigmon K, Anderson KM, Lee KL, Willerson JT on behalf of the EPIC Investigators (1994) Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months. Lancet 343: 881-886
107. Tschoepe D, Schultheiß HP, Kolarov P, Schippert B, Dannehl K, Nieuwenhuis HK, Kehrel B, Strauer BE, Gries FA (1993) Platelet membrane activation markers are predictive for an increased risk of acute ischemic events after PTCA. Circulation 88: 38-42
108. Turner NA, Moake JL, Kamat SG, Schafer AI, Kleiman NS, Jordan R, McIntire LV (1995) Comparative realtime effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin and monoclonal antibody fragment against glycoproetein IIb/IIIa. Circulation 91: 1354-1362
109. Urban P, Buller N, Fox K, Shapiro L, Bayliss L, Rickards A (1988): Lack of effect of warfarin on the restenosis rate or on clinical outcome after balloon coronary angioplasty. Brit Heart J 60: 485-488
110. Veen G, Meyer A, Verbeugt FWA, Werter CJPJ, DeSwart H, Lie KI, Van der Pol JMJ, Michels R, van Eeninge MJ (1993) Culprit lesion morphology and stenosis severity in the prediction of reocckision after thrombolysis: angiographic results of the APRICOT Study. J Am Coll Cardiol 22: 1755-1762
111. Violaris AG, Melkert R, Herrman JPR, Serruys PW (1996) Role of angiographically identifiable thrombus on long-term luminal renarrowing after coronary angioplasty - A quantitative angiographic analysis. Circulation 93: 889-897
112. Waller BF, Johnson DE, Schnit SJ, Pinkerton CA, Simpson JB, Baim DS (1993) Histologic analysis of directional coronary atherectomy samples. A review of findings and their clinical relevance. Am J Cardiol 72: 80E-87E
113. Wearn JT (1923) Thrombosis of the coronary arteries and infarction of the heart. Am J Med Sci 165: 250-276
114. White CW, Knudson M, Schmidt D, Chrisholm RJ, Vandormael M, Morton B, Roy L, Khaja F, Reitman M and the Ticlopidine Study Group (1987) Neither Ticlopidine nor aspirindypiridamole prevents restenosis post PTCA: Results from a randomized placebo-controlled multicenter trial. Circulation 76(Suppl.): IV-213
115. White CJ, Ramee SR, Collins TJ, Escobar AE, Karsan A, Shaw D, Jain SP, Bass TA, Heuser RR, Teirstein PS, Bonan R, Walter PD, Smalling RW (1996) Coronary thrombi increase PTCA risk - Angiosocpy as a clinical tool. Circulation 93: 253-258